Radja Badji

Abstract Multi-omics promises to transform medicine by providing holistic disease insights through interacting molecular layers, involving DNA, RNA, proteins and metabolites. The underlying technologies have matured rapidly, currently enabling higher throughputs at lower costs. Yet as multi-omics moves from research to routine care, the central challenge is no longer data generation, but standardizing and interpreting complexity within health systems built for discrete tests.

INTRODUCTION Pharmacogenetics (PGx) stands at the forefront of precision medicine, offering an unprecedented opportunity to individualize pharmacotherapy.1 By leveraging genomic insights, PGx aims to optimize drug efficacy and minimize adverse drug reactions, ultimately enhancing patient-centered care.2 The incorporation of PGx testing into clinical practice, based on established drug-gene pairs, is now recommended by various PGx guideline groups, which is critical for maximizing patient...